Philip Low is Chairman and Chief Executive Officer of NeuroVigil, the award-winning wireless neurodiagnostics company headquartered in San Diego. At the University of Chicago, he invented novel neurosurgical techniques. At Harvard Medical School, he showed in 9 weeks that a collagen inhibitor could successfully neutralize the growth of fibroid tumors – he was 19 years old at the time. At the Salk Institute, he invented the SPEARS algorithm and authored a one-page PhD thesis: a solution to a longstanding problem in brainwave analysis.
Dr. Low holds dual appointments from the Stanford School of Medicine and the MIT Media Lab, as well as an extraordinary ability recognition in the field of brain signal detection from the United States Government. He was named President of the 1st International Congress on Alzheimer’s Disease and Advanced Neurotechnologies, held in Monaco in February 2010. His work has been featured in technical and popular articles including CNN, Forbes, The Economist and The New York Times. To bring his innovations to the market, Dr. Low founded NeuroVigil when he was still in graduate school and enlisted 4 Nobel Laureates and 3 Fortune 500 company founders. Under Dr. Low’s leadership, NeuroVigil won the 2008 UCSD Entrepreneurship Competition, the annual 2008 DFJ Venture Challenge, the 2010 CONNECT Most Innovative New Product Award in Life Sciences and Diagnostics for iBrainTM, a wireless iPod for the brain, used by some of the world’s top pharmaceutical companies with outpatient drug evaluations, and was identified by Fast Company as one of the Top Ten Most Innovative Companies in Health Care, worldwide. NeuroVigil successfully went to market in 2009.
For his contributions to Biomedicine and for his business leadership, Dr. Low has been recognized by the MIT Technology Review as one of the 35 world leading innovators under 35. Past recipients include the founders of Linux, Netscape, Paypal, Google and Facebook.